A 58-year-old man with severe COPD (FEV₁ 32% predicted, TLC 125% predicted, RV 165% predicted) and heterogeneous upper-lobe predominant emphysema on HRCT presents for evaluation of advanced lung disease. He has completed pulmonary rehabilitation and demonstrates low post-rehabilitation exercise capacity. His blood gases are normal (PaO₂ 65 mmHg, PaCO₂ 42 mmHg), and he is abstinent from smoking for 8 months. The structure marked **C** in the diagram represents the intervention most likely to provide survival benefit in this patient. Which of the following is the PRIMARY MECHANISM by which this intervention improves respiratory function in upper-lobe predominant emphysema?
A. Reduction of airway resistance through selective bronchodilation of segmental bronchi in the lower lobes
B. Restoration of diaphragmatic geometry and elastic recoil by resection of the most diseased upper-lobe tissue, improving chest wall mechanics
C. Prevention of dynamic airway collapse by increasing intrathoracic pressure during expiration
D. Elimination of ventilation-perfusion mismatch by obliterating all non-functional alveolar units
Explanation
Why "Restoration of diaphragmatic geometry and elastic recoil by resection of the most diseased upper-lobe tissue, improving chest wall mechanics" is right
The structure marked C — Lung Volume Reduction Surgery (LVRS) — operates through a fundamental physiologic principle: removal of ~20–35% of the most severely diseased upper-lobe lung tissue restores the mechanical advantage of the diaphragm and chest wall by reducing hyperinflation. In emphysema, the diaphragm becomes flattened and mechanically disadvantaged due to severe hyperinflation (TLC >100% predicted, RV >150% predicted). LVRS restores elastic recoil of the remaining lung parenchyma and normalizes diaphragmatic curvature, allowing more efficient contraction. The landmark NETT trial (2003) demonstrated that this mechanism translates to improved exercise capacity, FEV₁, and 24-month survival in patients with upper-lobe heterogeneous disease and low post-rehabilitation exercise capacity — precisely the phenotype described in this case. The procedure is palliative, not curative, but addresses the core mechanical derangement of emphysema.
Why each distractor is wrong
"Reduction of airway resistance through selective bronchodilation of segmental bronchi in the lower lobes": LVRS does not work through bronchodilation; it is a surgical resection. Bronchodilation is a medical therapy (β₂-agonists, anticholinergics), not the mechanism of LVRS. This confuses pharmacologic with mechanical intervention.
"Prevention of dynamic airway collapse by increasing intrathoracic pressure during expiration": While dynamic airway collapse is a feature of emphysema, LVRS does not primarily work by increasing intrathoracic pressure. This describes the mechanism of pursed-lip breathing or positive expiratory pressure (PEP) devices, not surgical volume reduction.
"Elimination of ventilation-perfusion mismatch by obliterating all non-functional alveolar units": LVRS does not obliterate all non-functional units; it selectively resects the MOST diseased (upper-lobe) tissue while preserving relatively better-preserved lower-lobe lung. Complete obliteration would be counterproductive and is not the goal. This misrepresents the selective nature of the procedure.
High-YieldNEET PG
LVRS in upper-lobe heterogeneous emphysema works by restoring diaphragmatic geometry and elastic recoil through selective resection of the most diseased tissue — the NETT trial proved survival benefit in this exact phenotype (upper-lobe disease + low exercise capacity).
NEJM NETT 2003; ATS/ERS COPD guidelines
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
